Moderna will surge another 60% on the value of its potential coronavirus vaccine, according to one Wall Street firm (MRNA)

Moderna will surge another 60% on the value of its potential coronavirus vaccine, according to one Wall Street firm (MRNA)

Business Insider

Published

**

· *On Tuesday, Moderna announced that an early coronavirus vaccine trial produced antibodies in all participants.  *
· *Shares of Moderna surged as much as 18% on Wednesday. *
· *Piper Sandler on Wednesday raised its Moderna price target to $134, implying a more than 60% upside from current levels, on the potential...

Full Article